Bryan F. Cox

University of Westminster — United Kingdom

Medicine · Health Sciences

31h-index3.6kcitations116works3.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cardiac electrophysiology and arrhythmias(31), Ion channel regulation and function(21), Receptor Mechanisms and Signaling(12), Nitric Oxide and Endothelin Effects(11), Cardiac Ischemia and Reperfusion(11)

Publications116 total

Pressure enabled drug delivery (PEDD) of nelitolimod increased therapeutic delivery, reduced immunosuppression, and improved efficacy in porcine and murine liver tumor models
Frontiers in Oncology·2025· 1 citedOpen Access
Pressure-Enabled Drug Delivery Significantly Increases Intra-Arterial Delivery of Embolic Microspheres to Liver Tumors in a Porcine Model
Journal of Vascular and Interventional Radiology·2024· 2 cited
Intra-arterial Pressure-Enabled Drug Delivery Significantly Increases Penetration of Glass Microspheres in a Porcine Liver Tumor Model
Journal of Vascular and Interventional Radiology·2024· 6 citedOpen Access
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases
Journal for ImmunoTherapy of Cancer·2024· 6 citedOpen Access
PERIO-02: Phase 1b pressure enabled regional immuno-oncology trial of nelitolimod (SD-101), a class C TLR9 agonist, delivered via hepatic artery infusion +/- checkpoint inhibition in intrahepatic cholangiocarcinoma and hepatocellular carcinoma.
Journal of Clinical Oncology·2024· 4 cited
1123 Checkpoint inhibitor administered either systemically or subcutaneously enhances the anti-tumor immunity of SD-101 delivered by PEDD device in treating liver metastasis
Regular and Young Investigator Award Abstracts·2023Open Access
1534 Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial
2023· 4 citedOpen Access
Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model
Surgery·2023· 4 citedOpen Access
Abstract 5881: PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure- enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma
Cancer Research·2023· 2 cited
Abstract 1858: Enhanced delivery of anti PD-1 antibody to liver tumors in oncopig using pressure enabled drug delivery (PEDD) versus a systemic delivery
Cancer Research·2023· 1 cited
Pressure-Enabled Drug Delivery (PEDD) of a class C TLR9 agonist in combination with checkpoint inhibitor therapy in a murine pancreatic cancer model.
Journal of Clinical Oncology·2023· 1 cited
Regional infusion of a class C TLR9 agonist enhances liver tumor microenvironment reprogramming and MDSC reduction to improve responsiveness to systemic checkpoint inhibition
Cancer Gene Therapy·2022· 10 citedOpen Access
Oxaliplatin-induced peripheral neuropathy can be minimized by pressurized regional intravascular delivery in an orthotopic murine pancreatic cancer model
Discover Oncology·2022· 3 citedOpen Access
Oxaliplatin-Induced Peripheral Neuropathy Can Be Minimized By Pressurized Regional Intravascular Delivery In An Orthotopic Murine Pancreatic Cancer Model.
Research Square (Research Square)·2022Open Access
Antigen Receptor T Cells (CAR-T) Effectively Control Tumor Growth in a Colorectal Liver Metastasis Model
Journal of Surgical Research·2021· 9 cited
Regional Delivery of Anti-PD-1 Agent for Colorectal Liver Metastases Improves Therapeutic Index and Anti-Tumor Activity
Vaccines·2021· 4 citedOpen Access
Abstract 1793: Regional administration of class C CpG Oligodeoxynucleotides results in superior intrahepatic TLR9 activation and immunomodulation compared to systemic infusion
Cancer Research·2021· 1 cited
Applying CAPE to Assess Equitable CS Education
2021· 5 cited
Pressure-enabled delivery of gemcitabine in an orthotopic pancreatic cancer mouse model
Surgery·2020· 6 cited
Improved trafficking and tumor control with regional, pressure-enabled drug delivery of anti-CEA CAR-T cells for colorectal liver metastases in a murine model
The Journal of Immunology·2020
page 1 of 6Next →

Frequent Co-authors

Gary A. Gintant(15), James S. Polakowski(10), Ruth L. Martin(9), Jason A. Segreti(9), Zhi Su(8), Vincent P. Hradil(8), Glenn A. Reinhart(8), Yanping Luo(7), Ryan M. Fryer(7), Kennan C. Marsh(6), Jeff S. McDermott(6), Gerard B. Fox(6), James T. Limberis(5), Craig D. Wegner(5), Lee C. Preusser(5), Patricia N. Banfor(5), Kelly J. Larson(5), Philip R. Kym(5), Scott W. Mittelstadt(5), Michael F. Jarvis(4)